ES2159087T3 - Oxindoles sustituidos con adamantilo como agentes farmaceuticos. - Google Patents

Oxindoles sustituidos con adamantilo como agentes farmaceuticos.

Info

Publication number
ES2159087T3
ES2159087T3 ES97303343T ES97303343T ES2159087T3 ES 2159087 T3 ES2159087 T3 ES 2159087T3 ES 97303343 T ES97303343 T ES 97303343T ES 97303343 T ES97303343 T ES 97303343T ES 2159087 T3 ES2159087 T3 ES 2159087T3
Authority
ES
Spain
Prior art keywords
oxindols
adamantilo
replaced
pharmaceutical agents
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97303343T
Other languages
English (en)
Inventor
Joseph Peter Lyssikatos
Robert Alfred Volkmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2159087T3 publication Critical patent/ES2159087T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN METODO PARA TRATAR EL CANCER ADMINISTRANDO UN COMPUESTO DE LA FORMULA: EN DONDE R{SUP,1}, R{SUP,2}, R{SUP,3}, R{SUP,4}, R{SUP,5}, E{SUP,1}, E{SUP,2}, P, HET'' Y HET'''' SE DEFINEN COMO SE INDICA EN LA ESPECIFICACION.
ES97303343T 1996-05-28 1997-05-16 Oxindoles sustituidos con adamantilo como agentes farmaceuticos. Expired - Lifetime ES2159087T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1849096P 1996-05-28 1996-05-28

Publications (1)

Publication Number Publication Date
ES2159087T3 true ES2159087T3 (es) 2001-09-16

Family

ID=21788193

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97303343T Expired - Lifetime ES2159087T3 (es) 1996-05-28 1997-05-16 Oxindoles sustituidos con adamantilo como agentes farmaceuticos.

Country Status (9)

Country Link
EP (1) EP0810223B1 (es)
JP (1) JP3161994B2 (es)
AT (1) ATE203530T1 (es)
CA (1) CA2206104C (es)
DE (1) DE69705772T2 (es)
DK (1) DK0810223T3 (es)
ES (1) ES2159087T3 (es)
GR (1) GR3036968T3 (es)
PT (1) PT810223E (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025789A1 (en) * 1998-10-29 2000-05-11 Merck & Co., Inc. A method of treating endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876259A (en) * 1987-01-05 1989-10-24 E. I. Du Pont De Nemours And Company 3,3-disubstituted indolines
AU3425493A (en) * 1992-01-16 1993-08-03 Du Pont Merck Pharmaceutical Company, The Novel neurotransmitter releasers useful for cognition enhancement
EP0640072B1 (en) * 1992-05-15 2000-08-23 Btg International Limited Derivatives of pyridine as hydroxylase and lyase inhibitors
US5258401A (en) * 1992-07-10 1993-11-02 Merck & Co., Inc. Cholesterol lowering compounds
EP0763026B1 (en) * 1994-05-27 2003-03-26 James Black Foundation Limited Gastrin and cck antagonists
JPH09183725A (ja) * 1995-09-01 1997-07-15 Pfizer Inc ガン治療用治療剤

Also Published As

Publication number Publication date
DE69705772D1 (de) 2001-08-30
ATE203530T1 (de) 2001-08-15
PT810223E (pt) 2001-12-28
EP0810223B1 (en) 2001-07-25
DE69705772T2 (de) 2001-11-15
CA2206104C (en) 2000-05-30
DK0810223T3 (da) 2001-09-24
JP3161994B2 (ja) 2001-04-25
GR3036968T3 (en) 2002-01-31
JPH1045749A (ja) 1998-02-17
EP0810223A1 (en) 1997-12-03
CA2206104A1 (en) 1997-11-28

Similar Documents

Publication Publication Date Title
TR200000059T2 (tr) Piridin türevleri
DE69319976T2 (de) 7-Substituierte-9-substituierte Glycylamido-6-Demethyl-6-Deoxytetracycline
DK0842934T3 (da) 5-HT1F agonister
ATE215530T1 (de) 7-substituierte-8-substituierte-9-substituierte amino-7-demethyl-6-deoxy-tetracycline als antibiotische mittel
BR9804214A (pt) Compostos.
BR1100987A (pt) Composto, composição farmacêutica da matéria, e, composição veterinária
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
IL119207A0 (en) Treatment of tinnitus using neuroprotective agents
DE69716810T2 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
ID25478A (id) Agonis 5-ht1f
ES2159087T3 (es) Oxindoles sustituidos con adamantilo como agentes farmaceuticos.
ITMI930819A1 (it) Derivati eterobiciclici ad attivita' fungicida
EP0551844A3 (es)
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
BR9900024A (pt) Biciclo[3.1.0]hexanos e compostos relacionados.
DE69908855D1 (de) 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin
TR200003083T2 (tr) CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate.
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 810223

Country of ref document: ES